Research ExplorerPublicationsRibavirin for Hepatitis E Virus Infection After Organ Transp...

Ribavirin for Hepatitis E Virus Infection After Organ Transplantation: A Large European Retrospective Multicenter Study

Standard

Ribavirin for Hepatitis E Virus Infection After Organ Transplantation: A Large European Retrospective Multicenter Study. / Kamar, Nassim; Abravanel, Florence; Behrendt, Patrick; Hofmann, Jörg; Pageaux, Georges Phillippe; Barbet, Christelle; Moal, Valérie; Couzi, Lionel; Horvatits, Thomas; De Man, Robert A; Cassuto, Elisabeth; Elsharkawy, Ahmed M; Riezebos-Brilman, Annelies; Scemla, Anne; Hillaire, Sophie; Donnelly, Mhairi C; Radenne, Sylvie; Sayegh, Johnny; Garrouste, Cyril; Dumortier, Jérôme; Glowaki, François; Matignon, Marie; Coilly, Audrey; Figueres, Lucile; Mousson, Christiane; Minello, Anne; Dharancy, Sébastien; Rerolle, Jean Philippe; Lebray, Pascal; Etienne, Isabelle; Perrin, Peggy; Choi, Mira; Marion, Olivier; Izopet, Jacques; Hepatitis E Virus Ribavirin Study Group .

In: CLIN INFECT DIS, Vol. 71, No. 5, 22.08.2020, p. 1204-1211.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Kamar, N, Abravanel, F, Behrendt, P, Hofmann, J, Pageaux, GP, Barbet, C, Moal, V, Couzi, L, Horvatits, T, De Man, RA, Cassuto, E, Elsharkawy, AM, Riezebos-Brilman, A, Scemla, A, Hillaire, S, Donnelly, MC, Radenne, S, Sayegh, J, Garrouste, C, Dumortier, J, Glowaki, F, Matignon, M, Coilly, A, Figueres, L, Mousson, C, Minello, A, Dharancy, S, Rerolle, JP, Lebray, P, Etienne, I, Perrin, P, Choi, M, Marion, O, Izopet, J & Hepatitis E Virus Ribavirin Study Group 2020, 'Ribavirin for Hepatitis E Virus Infection After Organ Transplantation: A Large European Retrospective Multicenter Study', CLIN INFECT DIS, vol. 71, no. 5, pp. 1204-1211. https://doi.org/10.1093/cid/ciz953

APA

Kamar, N., Abravanel, F., Behrendt, P., Hofmann, J., Pageaux, G. P., Barbet, C., Moal, V., Couzi, L., Horvatits, T., De Man, R. A., Cassuto, E., Elsharkawy, A. M., Riezebos-Brilman, A., Scemla, A., Hillaire, S., Donnelly, M. C., Radenne, S., Sayegh, J., Garrouste, C., ... Hepatitis E Virus Ribavirin Study Group (2020). Ribavirin for Hepatitis E Virus Infection After Organ Transplantation: A Large European Retrospective Multicenter Study. CLIN INFECT DIS, 71(5), 1204-1211. https://doi.org/10.1093/cid/ciz953

Vancouver

Kamar N, Abravanel F, Behrendt P, Hofmann J, Pageaux GP, Barbet C et al. Ribavirin for Hepatitis E Virus Infection After Organ Transplantation: A Large European Retrospective Multicenter Study. CLIN INFECT DIS. 2020 Aug 22;71(5):1204-1211. https://doi.org/10.1093/cid/ciz953

Bibtex

@article{d71a94de110f44a897607fbbab147989,
title = "Ribavirin for Hepatitis E Virus Infection After Organ Transplantation: A Large European Retrospective Multicenter Study",
abstract = "BACKGROUND: Ribavirin is currently recommended for treating chronic hepatitis E virus (HEV) infection. This retrospective European multicenter study aimed to assess the sustained virological response (SVR) in a large cohort of solid organ transplant (SOT) recipients with chronic HEV infection treated with ribavirin monotherapy (N = 255), to identify the predictive factors for SVR, and to evaluate the impact of HEV RNA mutations on virological response.METHODS: Data from 255 SOT recipients with chronic HEV infection from 30 European centers were analyzed. Ribavirin was given at the median dose of 600 (range, 29-1200) mg/day (mean, 8.6 ± 3.6 mg/kg/day) for a median duration of 3 (range, 0.25-18) months.RESULTS: After a first course of ribavirin, the SVR rate was 81.2%. It increased to 89.8% when some patients were offered a second course of ribavirin. An increased lymphocyte count at the initiation of therapy was a predictive factor for SVR, while poor hematological tolerance of ribavirin requiring its dose reduction (28%) and blood transfusion (15.7%) were associated with more relapse after ribavirin cessation. Pretreatment HEV polymerase mutations and de novo mutations under ribavirin did not have a negative impact on HEV clearance. Anemia was the main adverse event.CONCLUSIONS: This large-scale retrospective study confirms that ribavirin is highly efficient for treating chronic HEV infection in SOT recipients and shows that the predominant HEV RNA polymerase mutations found in this study do not affect the rate of HEV clearance.This large-scale retrospective study that included 255 solid organ transplant recipients confirms that ribavirin is highly efficient for treating chronic hepatitis E virus (HEV) infection and shows that HEV RNA polymerase mutations do not play a role in HEV clearance.",
author = "Nassim Kamar and Florence Abravanel and Patrick Behrendt and J{\"o}rg Hofmann and Pageaux, {Georges Phillippe} and Christelle Barbet and Val{\'e}rie Moal and Lionel Couzi and Thomas Horvatits and {De Man}, {Robert A} and Elisabeth Cassuto and Elsharkawy, {Ahmed M} and Annelies Riezebos-Brilman and Anne Scemla and Sophie Hillaire and Donnelly, {Mhairi C} and Sylvie Radenne and Johnny Sayegh and Cyril Garrouste and J{\'e}r{\^o}me Dumortier and Fran{\c c}ois Glowaki and Marie Matignon and Audrey Coilly and Lucile Figueres and Christiane Mousson and Anne Minello and S{\'e}bastien Dharancy and Rerolle, {Jean Philippe} and Pascal Lebray and Isabelle Etienne and Peggy Perrin and Mira Choi and Olivier Marion and Jacques Izopet and {Hepatitis E Virus Ribavirin Study Group} and Sven Pischke",
note = "{\textcopyright} The Author(s) 2019. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.",
year = "2020",
month = aug,
day = "22",
doi = "10.1093/cid/ciz953",
language = "English",
volume = "71",
pages = "1204--1211",
journal = "CLIN INFECT DIS",
issn = "1058-4838",
publisher = "Oxford University Press",
number = "5",

}

RIS

TY - JOUR

T1 - Ribavirin for Hepatitis E Virus Infection After Organ Transplantation: A Large European Retrospective Multicenter Study

AU - Kamar, Nassim

AU - Abravanel, Florence

AU - Behrendt, Patrick

AU - Hofmann, Jörg

AU - Pageaux, Georges Phillippe

AU - Barbet, Christelle

AU - Moal, Valérie

AU - Couzi, Lionel

AU - Horvatits, Thomas

AU - De Man, Robert A

AU - Cassuto, Elisabeth

AU - Elsharkawy, Ahmed M

AU - Riezebos-Brilman, Annelies

AU - Scemla, Anne

AU - Hillaire, Sophie

AU - Donnelly, Mhairi C

AU - Radenne, Sylvie

AU - Sayegh, Johnny

AU - Garrouste, Cyril

AU - Dumortier, Jérôme

AU - Glowaki, François

AU - Matignon, Marie

AU - Coilly, Audrey

AU - Figueres, Lucile

AU - Mousson, Christiane

AU - Minello, Anne

AU - Dharancy, Sébastien

AU - Rerolle, Jean Philippe

AU - Lebray, Pascal

AU - Etienne, Isabelle

AU - Perrin, Peggy

AU - Choi, Mira

AU - Marion, Olivier

AU - Izopet, Jacques

AU - Hepatitis E Virus Ribavirin Study Group

AU - Pischke, Sven

N1 - © The Author(s) 2019. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.

PY - 2020/8/22

Y1 - 2020/8/22

N2 - BACKGROUND: Ribavirin is currently recommended for treating chronic hepatitis E virus (HEV) infection. This retrospective European multicenter study aimed to assess the sustained virological response (SVR) in a large cohort of solid organ transplant (SOT) recipients with chronic HEV infection treated with ribavirin monotherapy (N = 255), to identify the predictive factors for SVR, and to evaluate the impact of HEV RNA mutations on virological response.METHODS: Data from 255 SOT recipients with chronic HEV infection from 30 European centers were analyzed. Ribavirin was given at the median dose of 600 (range, 29-1200) mg/day (mean, 8.6 ± 3.6 mg/kg/day) for a median duration of 3 (range, 0.25-18) months.RESULTS: After a first course of ribavirin, the SVR rate was 81.2%. It increased to 89.8% when some patients were offered a second course of ribavirin. An increased lymphocyte count at the initiation of therapy was a predictive factor for SVR, while poor hematological tolerance of ribavirin requiring its dose reduction (28%) and blood transfusion (15.7%) were associated with more relapse after ribavirin cessation. Pretreatment HEV polymerase mutations and de novo mutations under ribavirin did not have a negative impact on HEV clearance. Anemia was the main adverse event.CONCLUSIONS: This large-scale retrospective study confirms that ribavirin is highly efficient for treating chronic HEV infection in SOT recipients and shows that the predominant HEV RNA polymerase mutations found in this study do not affect the rate of HEV clearance.This large-scale retrospective study that included 255 solid organ transplant recipients confirms that ribavirin is highly efficient for treating chronic hepatitis E virus (HEV) infection and shows that HEV RNA polymerase mutations do not play a role in HEV clearance.

AB - BACKGROUND: Ribavirin is currently recommended for treating chronic hepatitis E virus (HEV) infection. This retrospective European multicenter study aimed to assess the sustained virological response (SVR) in a large cohort of solid organ transplant (SOT) recipients with chronic HEV infection treated with ribavirin monotherapy (N = 255), to identify the predictive factors for SVR, and to evaluate the impact of HEV RNA mutations on virological response.METHODS: Data from 255 SOT recipients with chronic HEV infection from 30 European centers were analyzed. Ribavirin was given at the median dose of 600 (range, 29-1200) mg/day (mean, 8.6 ± 3.6 mg/kg/day) for a median duration of 3 (range, 0.25-18) months.RESULTS: After a first course of ribavirin, the SVR rate was 81.2%. It increased to 89.8% when some patients were offered a second course of ribavirin. An increased lymphocyte count at the initiation of therapy was a predictive factor for SVR, while poor hematological tolerance of ribavirin requiring its dose reduction (28%) and blood transfusion (15.7%) were associated with more relapse after ribavirin cessation. Pretreatment HEV polymerase mutations and de novo mutations under ribavirin did not have a negative impact on HEV clearance. Anemia was the main adverse event.CONCLUSIONS: This large-scale retrospective study confirms that ribavirin is highly efficient for treating chronic HEV infection in SOT recipients and shows that the predominant HEV RNA polymerase mutations found in this study do not affect the rate of HEV clearance.This large-scale retrospective study that included 255 solid organ transplant recipients confirms that ribavirin is highly efficient for treating chronic hepatitis E virus (HEV) infection and shows that HEV RNA polymerase mutations do not play a role in HEV clearance.

U2 - 10.1093/cid/ciz953

DO - 10.1093/cid/ciz953

M3 - SCORING: Journal article

C2 - 31793638

VL - 71

SP - 1204

EP - 1211

JO - CLIN INFECT DIS

JF - CLIN INFECT DIS

SN - 1058-4838

IS - 5

ER -